A Study to Test GlaxoSmithKline's (GSK) Herpes Zoster (HZ) Subunit Vaccine's Long-term Immune Response in Previously Vaccinated Kidney Transplant Adults and Then to Test if 2 Additional Doses of the Vaccine Are Safe and Able to Generate an Immune Response

Summary

The purpose of this study was to evaluate the long-term immune responses to the Herpes Zoster subunit (HZ/su) vaccine as well as safety up to 7 years after the 2-dose primary vaccination course from study ZOSTER-041 (NCT02058589). This study also assessed immune responses as well as safety after revaccination with 2 additional doses of the HZ/su administered at 6 to 8 years after the 2-dose primary vaccination course.

Timeline

Start

2019-12-09

Primary completion

2022-08-12

Completion

2024-06-27

Publications

• Hutton MM, Vink PE, Kuxhausen A, Tsang M, Sanchez Fructuoso A, Robberechts T, Perez R, Park JB, Ortiz F, Kumar D, Chiang YJ, Atig F, Mwakingwe-Omari A; Zoster-073 study group. Long-term immunogenicity and safety of RZV primary vaccination and revaccination in kidney transplant recipients. J Infect. 2026 Jul;93(1):106758. doi: 10.1016/j.jinf.2026.106758. Epub 2026 May 14.

Drugs

Indications